Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
GRTX

GRTX - Galera Therapeutics Inc Stock Price, Fair Value and News

$0.05+0.01 (+25.00%)
Market Closed

Price Targets

GRTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GRTX Price Action

Last 7 days

25%

Last 30 days

150%

Last 90 days

150%

Trailing 12 Months

25%

GRTX RSI Chart

GRTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GRTX Valuation

Market Cap

3.8M

Price/Earnings (Trailing)

-0.42

EV/EBITDA

0.04

Price/Free Cashflow

-0.56

MarketCap/EBT

-0.21

GRTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

GRTX Fundamentals

GRTX Earnings

Earnings (TTM)

-9.0M

Earnings Growth (Yr)

75.13%

Earnings Growth (Qtr)

-29.12%

GRTX Profitability

Return on Equity

-146.88%

Return on Assets

-179.65%

Free Cashflow Yield

-179.96%

GRTX Investor Care

Shares Dilution (1Y)

38.74%

Diluted EPS (TTM)

-0.1

About Galera Therapeutics Inc

GRTX
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
 CEO
 WEBSITEgaleratx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES31

Galera Therapeutics Inc Frequently Asked Questions

GRTX is the stock ticker symbol of Galera Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Galera Therapeutics Inc is 3.77 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.